Specifications - Chugai Pharmaceutical Bulk Antibody Production Plant, Utsunomiya, Japan

Key Data
Location	Utsunomiya, Japan
Estimated investment	¥14.96 billion
Completion	Phase one Q1 2003, Phase two Q2 2005, Phase three 2008
Start of operations	Phase one Q1 2004, Phase two Q2 2006, Phase three 2008+
Output chemicals	Monoclonal antibodies and recombinant proteins
Plant capacity	80,000L following phase two but will expand to in excess of 90,000L
Key Players
Sponsor	Chugai Pharmaceutical Co. Ltd
Lead engineer / designer	Hitachi Ltd
Validation	Hitachi Ltd, Amersham Biosciences (Fast Track)
Featured Suppliers
Applikon Biotechnology - Bioreactor Systems